Abiraterone or Docetaxel Plus Androgen Deprivation in Hormone-Sensitive Prostate Cancer: More Questions Than Answers
- PMID: 29128209
- DOI: 10.1016/j.eururo.2017.10.028
Abiraterone or Docetaxel Plus Androgen Deprivation in Hormone-Sensitive Prostate Cancer: More Questions Than Answers
Comment on
-
Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis.Eur Urol. 2018 Jun;73(6):834-844. doi: 10.1016/j.eururo.2017.10.002. Epub 2017 Oct 14. Eur Urol. 2018. PMID: 29037513
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
